[go: up one dir, main page]

MX2025005378A - Metodos para el tratamiento de enfermedades cardiovasculares - Google Patents

Metodos para el tratamiento de enfermedades cardiovasculares

Info

Publication number
MX2025005378A
MX2025005378A MX2025005378A MX2025005378A MX2025005378A MX 2025005378 A MX2025005378 A MX 2025005378A MX 2025005378 A MX2025005378 A MX 2025005378A MX 2025005378 A MX2025005378 A MX 2025005378A MX 2025005378 A MX2025005378 A MX 2025005378A
Authority
MX
Mexico
Prior art keywords
methods
treatment
cardiovascular disease
cardiovascular diseases
antibody
Prior art date
Application number
MX2025005378A
Other languages
English (en)
Inventor
Sandeep Kulkarni
Yung Chyung
Susan Dana Jones
Ryan Iarrobino
W Bradford Middlekauff
Original Assignee
Tourmaline Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tourmaline Bio Inc filed Critical Tourmaline Bio Inc
Publication of MX2025005378A publication Critical patent/MX2025005378A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona métodos para tratar enfermedades cardiovasculares que comprenden administrar por vía subcutánea a un paciente que lo necesite una dosis terapéuticamente eficaz de un anticuerpo o fragmento de anticuerpo anti-interleucina-6 (anti-IL-6). Además, se proporcionan en el presente documento agentes farmacológicamente activos, composiciones, métodos y/o esquemas de dosificación para el tratamiento de enfermedades cardiovasculares.
MX2025005378A 2022-11-11 2025-05-08 Metodos para el tratamiento de enfermedades cardiovasculares MX2025005378A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263383429P 2022-11-11 2022-11-11
US202363586027P 2023-09-28 2023-09-28
PCT/US2023/078948 WO2024102732A1 (en) 2022-11-11 2023-11-07 Methods for the treatment of cardiovascular disease

Publications (1)

Publication Number Publication Date
MX2025005378A true MX2025005378A (es) 2025-06-02

Family

ID=91033435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025005378A MX2025005378A (es) 2022-11-11 2025-05-08 Metodos para el tratamiento de enfermedades cardiovasculares

Country Status (9)

Country Link
US (1) US20250011416A1 (es)
EP (1) EP4615867A1 (es)
JP (1) JP2025539262A (es)
KR (1) KR20250107839A (es)
CN (1) CN120265653A (es)
AU (1) AU2023375340A1 (es)
MX (1) MX2025005378A (es)
TW (1) TW202428611A (es)
WO (1) WO2024102732A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025072725A1 (en) * 2023-09-28 2025-04-03 Tourmaline Bio, Inc. Methods for the treatment of cardiovascular disease
CN120581225B (zh) * 2025-08-04 2025-11-14 陕西省人民医院(陕西省临床医学研究院) 一种基于协同采集的心脑血管疾病筛查系统及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
NZ739392A (en) * 2015-07-31 2019-10-25 Medimmune Ltd Methods for treating hepcidin-mediated disorders

Also Published As

Publication number Publication date
TW202428611A (zh) 2024-07-16
EP4615867A1 (en) 2025-09-17
KR20250107839A (ko) 2025-07-14
AU2023375340A1 (en) 2025-05-15
CN120265653A (zh) 2025-07-04
WO2024102732A1 (en) 2024-05-16
US20250011416A1 (en) 2025-01-09
JP2025539262A (ja) 2025-12-04

Similar Documents

Publication Publication Date Title
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
ECSP045430A (es) Terapia de combinación para el tratamiento de cancer
CO5700791A2 (es) Metodos para tratar enfermedades relacionadas con interleukin-6
AR050418A1 (es) Dosificacion fija de anticuerpos her
CY1115046T1 (el) Καινουργια sirnas και μεθοδοι χρησης αυτων
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
CL2024003729A1 (es) Terapia combinada de agente activo anti-pd-1, agente activo anti-tim-3 y agente activo anti-lag-3 para tratar cáncer.
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2025003052A (es) Polipeptido analgesico
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MX2025005176A (es) Metodos para el tratamiento de la obesidad
PE20240777A1 (es) Proteinas actrii y usos de las mismas
MX2025006279A (es) Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a
WO2024112527A3 (en) Methods for the treatment of thyroid eye disease
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
MX2024010392A (es) Remibrutinib para el uso en el tratamiento de hidradenitis supurativa.
DOP2023000216A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
UY40364A (es) Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma
MX2024011932A (es) Combinaciones farmaceuticas y metodos de uso del compuesto de amino-pirrolopirimidinona